Compugen (CGEN) investor relations material

Introduction and agenda

• Discussion focused on transforming predictive biology into first-in-class immuno-oncology drugs, with emphasis on computational target discovery and the unique aspects of the platform.

Background and experience of the speaker

• The speaker highlighted decades of experience in computational biology, predating the current AI trend in biotech.

Current industry trends

• Many companies now claim AI/data advantages, but few focus on novel target discovery at the earliest R&D stages.

• The industry is shifting toward combination therapies in oncology, with a focus on new mechanisms and improved safety profiles.

• There is increasing competition from China and a trend of pharma companies clustering around the same targets.